drugset / Trial / NCT00217178

Homocysteine Lowering and Atherosclerosis Reduction Trial (HART)

NCT00217178

RandomizedFactorialDouble-blindPrevention

Summary

Study Objective: 1\. To evaluate whether combined therapy with folic acid 2.5 mg/day, vitamin B6 50 mg/day and vitamin B12 1000 micrograms/day vs placebo reduces the rate of atherosclerosis progression, as evaluated by quantitative B-mode carotid ultrasound (US).

Timeline

Start
2000-01
Primary completion
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject B12 Other / unclassified 1000 ug
Subject B6 Other / unclassified 50 mg
Subject folic acid Other / unclassified 2.5 mg

Indications